Prostate Cancer
Antisense therapy targeting MDM2 oncogene shuts down prostate malignancy
Published in Gene Therapy Weekly, November 27th, 2003
According to researchers in the United States, "this study was undertaken to investigate the role of mouse double minute 2 (MDM2) oncogene in prostate cancer growth and the potential of MDM2 as a target for prostate cancer therapy. An antisense anti-human-MDM2 mixed-backbone oligonucleotide was tested in human prostate cancer models with various p53 statuses, LNCaP (p53(wt/wt)), DU145 (p53(mt/mt)), and PO (p53(null)). In a dose- and time-dependent manner, it specifically inhibited MDM2 expression and modified expression of several genes, at both mRNA and protein levels."
"In...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2003-11-27)
More Articles from Gene Therapy Weekly
- Antisense Technology
Bcl-x(L) antisense oligonucleotides sensitize colon cancer cells to radiation - Immunology
A combination of interleukins causes metastatic lymphoma regression - Cancer Therapy
PTEN gene delivery inhibits human colorectal cancer growth - Fetal Medicine
In utero gene therapy leads to long-term correction of metabolic disease - Gene Transfer
Modified adenovirus proves capable of transducing susceptible cells better - Angiology
The eye is a valuable tool for the study of angiogenesis - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
